Home Metabolism COMT inhibitor Tolcapone

research use only

Tolcapone COMT inhibitor

Cat.No.S4021

Tolcapone (Ro 40-7592) is a selective, potent and reversible of catechol-O-methyl transferase (COMT) inhibitor with Ki of 30 nM.
Tolcapone COMT inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 273.24

Jump to

Quality Control

Batch: S402101 DMSO]55 mg/mL]false]Ethanol]55 mg/mL]false]Water]Insoluble]false Purity: 99.91%
  • Cited in Nature Medicine for its top-tier quality
  • COA
  • NMR
  • HPLC
  • SDS
  • Datasheet
99.91

Solubility

In vitro
Batch:

DMSO : 55 mg/mL (201.28 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 55 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 273.24 Formula

 

C14H11NO5
 Storage (From the date of receipt)
CAS No. 134308-13-7 Download SDF Storage of Stock Solutions

Synonyms Ro 40-7592 Smiles CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]

Mechanism of Action

Targets/IC50/Ki
COMT
30 nM(Ki)
In vitro
Tolcapone functions as a selective peripheral and central COMT inhibitor, exerting no effect on adrenergic, serotonergic, or cholinergic receptors or other enzymes involved in synthesis or catabolism of catecholamines. This compound produces a concentration-dependent decrease in COMT activity in liver homogenates of developing (3 days-old) and adult (60 days-old) rats with Vmax, Km and IC50 of 5.3 nM/mg/h, 3.3 μM, 41 nM, and 2.9 nM/mg/h, 13.1 μM, 720 nM, respectively. It also produces a concentration-dependent decrease in COMT activity in kidney of developing (3 days-old) and adult (60 days-old) rats with Vmax, Km and IC50 of 2.6 nM/mg/h, 2.7 μM, 8 nM, and 3.5 nM/mg/h, 24 μM, 177 nM, respectively.
In vivo
Tolcapone orally administrated is able to crosses the blood-brain barrier. Acute administration of this compound increases basal levels of L-DOPA and dihydroxyphenylacetic acid (DOPAC) and decreases basal homovanillic acid (HVA) levels, but does not affect basal dopamine levels. This compound (30 mg/kg p.o.) combined with benserazide (15 mg/kg p.o.) and a low dose of L-dopa (10 mg/kg p.o.) almost completely blockes (for about 6 h) the formation of 3-O-methyldopa (3-OMD) in brain and plasma, producing a long-lasting increase of L-DOPA in plasma and a parallel marked increase of L-DOPA and dopamine in the brain. It displays behavioural and neurochemical benefits on animals. This chemical (30 mg/kg p.o.) increases the effect of L-DOPA (plus benserazide) on locomotor activity, reserpine-induced hypothermia, and catalepsy induced by pimozide, haloperidol and fluphenazine. It also increases locomotor hyperactivity induced by amphetamine or nomifensine, as well as stereotypy induced by amphetamine (but not apomorphine).
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/2089102/
  • [5] https://pubmed.ncbi.nlm.nih.gov/1977408/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03591757 Completed
Transthyretin Amyloidosis|Amyloidosis Leptomeningeal Transthyretin-Related
Boston University|Corino Therapeutics Inc.
 October 30 2018 Early Phase 1
NCT02630043 Terminated
Neuroblastoma
Giselle Sholler|Milton S. Hershey Medical Center
 December 2015 Phase 1
NCT02929485 Withdrawn
Addiction
University of California Berkeley|University of California San Francisco
 July 2013 Phase 4
NCT02080715 Completed
Healthy
University of Zurich
 June 2013 Phase 1
NCT00604591 Completed
Frontotemporal Lobar Degeneration
Columbia University|National Institute of Neurological Disorders and Stroke (NINDS)
 July 2011 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.